JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saleem, R.
Right arrow Articles by Despotis, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saleem, R.
Right arrow Articles by Despotis, G. J.
Anesth Analg 2000;90:1281-1285
© 2000 International Anesthesia Research Society

CARDIOVASCULAR ANESTHESIA

The Effect of Epsilon-Aminocaproic Acid on HemoSTATUS® and Kaolin-Activated Clotting Time Measurements

Rao Saleem, MD*, Matthew Bigham, MD*, Edward Spitznagel, PhD{ddagger}, and George J. Despotis, MD*,{dagger}

Departments of *Anesthesiology and {dagger}Immunology and Pathology, {ddagger}Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri

Address correspondence and reprint requests to George Despotis, MD, Department of Anesthesiology, Box 8054, Washington University School of Medicine, 660 South Euclid Ave., St. Louis, MO 63110.

New point-of-care assays have been used to identify patients with heparin resistance (i.e. heparin dose response test; Medtronic Blood Management, Parker, CO) and who have platelet dysfunction (i.e. HemoSTATUS®; Medtronic Blood Management). We examined the effect of epsilon-aminocaproic acid on results from these two point-of-care tests in patients undergoing cardiac surgery. Twenty patients scheduled for elective cardiac surgical procedures were enrolled in this prospective study. HemoSTATUS® clot ratio (% maximal) values in Channels (Ch) 3–6 (Ch 3: 26 ± 25, Ch 4: 66 ± 23, Ch 5: 84 ± 20, Ch 6: 106 ± 18) obtained after the IV administration of epsilon-aminocaproic acid were similar to values obtained before the administration of this agent (Ch 3: 26 ± 20, Ch 4: 69 ± 23, Ch 5: 86 ± 19, Ch 6: 109 ± 14). Slope values (86 ± 23 s · U-1 · mL-1) and projected heparin concentrations (4 ± 1 U/mL) obtained before the administration of epsilon-aminocaproic acid were similar to slope values (88 ± 21 s · U-1 · mL-1) and projected heparin concentrations (4 ± 1 U/mL) values obtained after administration of this agent. Our data indicate that HemoSTATUS® clot ratio values and heparin dose response values are not significantly affected after IV dosing of epsilon-aminocaproic acid.

Implications: Values from two activated coagulation time-based test systems used to identify significant heparin resistance or platelet dysfunction after cardiopulmonary bypass were not significantly affected by epsilon-aminocaproic acid administered IV.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
B. S. Donahue
Factor V Leiden and Perioperative Risk
Anesth. Analg., June 1, 2004; 98(6): 1623 - 1634.
[Abstract] [Full Text] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 2000 by the International Anesthesia Research Society.